Supplied as model SCPP-98-PH, (S)-(-)-3-chloro-1-phenyl-1-propanol is a chiral C9 chloro alcohol with molecular formula C9H11ClO and relative molecular mass 170.64 g/mol. The compound is manufactured under ICH Q7 for pharmaceutical-grade use and is designated for oral tablet, capsule, granule, and injectable dosage forms. At 20–25 °C the material is a low-viscosity oil; this physical state requires adsorption onto a porous excipient before direct mixing into solid dosage forms, because uncontrolled liquid loading causes segregation and punch filming. The stereochemical configuration follows the Cahn-Ingold-Prelog assignment at C-1, and the optical rotation is negative at the sodium D-line. The C-1 chiral centre is the reactive alcohol function; downstream etherification, esterification, or sulfonylation preserves the (S) configuration, whereas oxidation converts it to the prochiral ketone. This sign differentiates the (S)-(-) form from both the (R)-(+) enantiomer and the racemic mixture, which are available as fine chemical intermediates but are not interchangeable in chiral arylpropanolamine synthesis.

What Limits Chiral Purity of (S)-(-)-3-chloro-1-phenyl-1-propanol in Oral and Injectable Doses?

The chiral centre at C-1 is controlled by chiral HPLC using a cellulose tris(3,5-dimethylphenylcarbamate) stationary phase with an n-heptane/2-propanol 90:10 v/v mobile phase and detection at 210 nm. Enantiomeric excess is determined by area normalization against a pre-qualified reference standard; release of model SCPP-98-PH requires ≥99.0% enantiomeric excess with the (R)-(+)-isomer limited to ≤0.5%. Related substances are quantified by GC or HPLC with a sample concentration of 1.0 mg/mL in acetonitrile. Any unspecified impurity is controlled at ≤0.10%, and total impurities are ≤0.50%. The chiral purity specification is critical because residual (R)-enantiomer can form diastereomeric downstream intermediates with altered salt resolution, which reduces isolated yield and can alter the pharmacological profile of the resulting arylpropanolamine derivative. The method is performed according to USP <621>; method qualification includes forced degradation under acidic, alkaline, oxidative, and thermal conditions to ensure resolution between the S and R forms and the elimination product 1-phenylprop-2-en-1-ol.

Stability data generated under ICH Q1A conditions were evaluated for a liquid-filled capsule formulation. After 6 months at 40 °C/75% RH, total related substances increased from 0.22% to 0.48%; the (R)-isomer content remained below 0.5%. No new impurity exceeding 0.10% was observed. These data support secondary packaging with desiccant and cold-chain storage for prolonged stability.

Production-scale observations from a 500 L glass-lined reactor indicate that the reaction mass remains homogeneous when the pH is kept below 7.0 during the final extraction; phase separation times increase from 20 min to over 90 min when the pH exceeds 8.0 because of partial emulsification. The API is packaged in fluoropolymer-lined epoxy drums with nitrogen blanket; analytical samples are withdrawn through a dip tube to avoid atmospheric moisture ingress. Each shipment includes a certificate of analysis referencing the DMF number and the chiral HPLC chromatogram. For tablet and capsule manufacturers, 21 CFR 211.84 requires identity testing of each lot; the recommended identity test is chiral HPLC retention time matching plus optical rotation. This field data is relevant because residual water or pH excursions during work-up can reduce enantiomeric purity and increase related substances before the material reaches the dosage form.

Residual Solvent, Water, and Elemental Impurity Specification Set

Across the three principal dosage forms, water content is treated as a critical quality attribute because residual water accelerates dehydrohalogenation of the chloro alcohol to 1-phenylprop-2-en-1-ol under mildly alkaline or elevated-temperature conditions. Karl Fischer titration according to USP <921> Method Ia controls water at ≤0.50%. Residual solvents are measured by headspace gas chromatography using USP <467> Procedure A and ICH Q3C limits; methanol, dichloromethane, and toluene are monitored as class 1/2 solvent constituents. Consistent with ICH Q3C, the permitted daily exposure for methanol is 30.0 mg/day, for dichloromethane 6.0 mg/day, and for toluene 8.9 mg/day; these values are used to derive concentration limits for the API based on intended dose. The headspace GC method uses a 0.32 mm internal diameter fused-silica column coated with a 1.8 µm film of 6% cyanopropylphenyl/94% dimethylpolysiloxane; split ratio is 20:1, column flow 2.5 mL/min helium. Elemental impurities are determined by inductively coupled plasma mass spectrometry according to USP <232> and USP <233>, with lead, cadmium, arsenic, and mercury limited to ≤5, ≤1, ≤1.5, and ≤0.5 ppm, respectively. Sulfated ash is controlled at ≤0.10% according to USP <281>. Table 1 summarizes the release specification matrix; the values are maximum limits, not target values, except where a range is explicitly stated.

Compared with the (R)-(+)-isomer and the racemic 3-chloro-1-phenyl-1-propanol mixture, the (S)-(-) material is distinguished by the sign of optical rotation, by its behaviour in chiral salt resolution, and by its suitability for routes that require an (S)-configured arylpropanolamine synthon. The racemic mixture cannot be substituted in enantioselective crystallization without introducing up to 50% of the undesired enantiomer. The (R)-isomer, even at 0.5–1.0% contamination, may alter the solid-state habit of a downstream diastereomeric salt and reduce isolated yield. In capsule filling, the liquid nature of this API differentiates it from crystalline propanolamine intermediates: it requires adsorption or conversion into a granule before use in automatic capsule filling machines. Unlike 3-chloro-1-phenylpropan-1-one, which is a ketone with different reactivity, this alcohol retains a chiral secondary alcohol function through subsequent etherification or amination steps; this avoids a separate reduction step after ketone formation and reduces borane-derived residual impurities. In contrast, the enantiomeric pair has identical molecular weight, boiling point, and solubility, but opposite optical rotation; therefore, only chiral HPLC or optical rotation can distinguish them. The racemic mixture may also have different residual solvent profiles if sourced from an unregulated fine chemical supply chain. Table 2 summarizes the comparative differentiation matrix.

When Dry Granulation and Direct Compression Require Adsorption onto Porous Carriers

When dry granulation is used, the liquid API is first adsorbed onto a porous excipient such as silicified microcrystalline cellulose or dibasic calcium phosphate anhydrous. A typical liquid load of 5–20 wt% is used; loadings above 20 wt% produce overwetted granules that adhere to roller compactor rolls and reduce ribbon tensile strength below 0.5 MPa. The adsorbed powder is passed through a 0.8 mm screen before roller compaction at roll force 8–15 kN/cm and roll speed 3–7 rpm. Granule size after milling is controlled to D50 100–250 µm; a D50 below 100 µm improves content uniformity but decreases flow. For capsule filling, the granules are filled using a tamping-pin capsule machine with pin height adjusted to achieve fill weight RSD ≤3.0%. If direct compression is required, dry granulation is generally necessary because the neat oil cannot be compressed directly; direct compression with unadsorbed liquid fails tablet hardness specifications and causes punch filming within 10 min of compression. If a crystalline solid dosage form without adsorption is required, a crystalline salt or covalent derivative of the API may be considered, but the chiral alcohol itself is not suitable as a dry direct-compression powder. Published data for this specific API configuration is limited; the cited ranges are typical for liquid-loaded granulation and must be requalified per product.

For injectable use, the API is dissolved in a solvent matrix typically composed of polyethylene glycol 300, ethanol, and water for injection; the final product is sterilized by filtration through a 0.22 µm PVDF membrane. Endotoxin is controlled by the K/M calculation from USP <85>; if the maximum adult dose is 50 mg/kg, the release limit is 0.10 EU/mg based on K=5 EU/kg. The solution is filled into depyrogenated glass vials with nitrogen overlay to limit oxidative degradation of the secondary alcohol to the corresponding ketone. Particulate matter is assessed according to USP <788>; counts for particles ≥10 µm and ≥25 µm are controlled below the harmonized light obscuration numbers. For oral granules, the adsorbed material is drum-blended and filled into sachets with desiccant; water activity above 0.40 activates degradation, so sachet seals are tested at 0.12 mm polyethylene film thickness. Batch-to-batch variance for water content across three commercial campaigns was 0.12–0.38% when drums were stored at 2–8 °C under nitrogen; opening a drum above 60% relative humidity raises water content by approximately 0.05% per 24 h. Therefore warehouse transfer and dispensing are conducted with dry nitrogen purge or in a relative humidity below 30%.